Study Objectives: Snakebite is a newly designated WHO, Class A, Neglected Tropical Disease. 75% of the nearly 100,000 annual deaths by snakebite occur in the out-of-hospital setting. 98% of snakebite victims and their livestock reside in impoverished communities. Antivenom is the only existing treatment for snakebite but requires hospital administration. A potent, broad-spectrum, heat stable, oral antidote to snakebite could address many of the limitations of antivenom and is desirable for improved outcomes, access to care, and for those whose occupation puts them at risk for snakebite in diverse settings (eg, military personnel and their working canines). We previously identified a small molecule with characteristics meeting criteria for a field antidote. LY315920, the parent compound of LY333013 inhibited more than 25 different snake venom sPLA2s from 6 continents (Lewin et al 2016) .
Our objective was to determine the efficacy of an orally bioavailable, broadspectrum sPLA2 inhibitor to rescue mice and pigs in an experimental model of lethal envenomation.
Methods: Mice and/or juvenile pigs were envenomed with 100% lethal doses of whole venom from medically important snakes (eg, coral snake (M. fulvius), sawscale viper (E. carinatus), Russell's viper (D. russelli), Mojave rattlesnake (C. scutulatus), neotropical rattlesnake (C. durissus terrificus), coastal taipan (O. scutellatus)) and then treated orally with 1 or multiple doses of LY333013 at various time points following experimental envenomation (range 1 minute to 2.5 hours depending on experiment).
Results: 98% of treated mice (N¼49/50) and outlived carrier (control, N¼32). The mice were observed for a minimum of 24 hours 100% of pigs survived to 96 hour endpoint (N¼5) with most requiring q6 hour oral antidote for the first 24 hours. All controls died within 8 hours. Two doses of drug were required to cure mice injected with E. carinatus sochureki, D. russelli, C. durissus terrificus, and O. scutellatus when drug was administered with an hour delay or more. For taipan, a single dose of oral drug given within 10 minutes was uniformly curative. Figure 1 shows 24 hour K-M in mice given single dose (10mg/kg) LY333013 orally within 30 minutes of experimental envenomation with coastal taipan venom.
Conclusions: LY333013 appears to have broad efficacy in animal models and can reverse neuromuscular paralysis even after onset of symptoms. Pre-clinical studies with experimental envenomation and its safety record in multiple Phase 1 and Phase 2 human clinical trials for other indications suggest it could be part of a solution to the global burden of disease caused by snakebite. Further exploration of its development as a field antidote and adjunct to antivenom is warranted. Study Objectives: Every year millions of children die in low-and middle-income countries (LMICs) from preventable causes. One solution to decreasing morbidity and mortality is out-of-hospital care in the form of organized emergency medical services (EMS). EMS is a critical but unrecognized component of public health infrastructure, but there is scant literature on EMS for pediatric patients in LMICs. We aimed to describe the epidemiology of pediatric emergency medical conditions seen by the largest EMS provider in India over 3 years (2013) (2014) (2015) .
Methods: We reviewed the dispatch records of a single EMS provider in India from January 1, 2013-December 31, 2015 across 12 states and union territories. We included all records for patients < 18 years. We excluded calls for pregnancy-related complaints, calls where there was no emergency medical technician (EMT) contact with the patient, and replicate case IDs. Calls without EMT contact included dispatches where the patient was not found, where the patient refused services, hoax calls, and erroneous dispatches. We included only the first instance of any replicated case ID. Case IDs may be replicated for incidents with multiple patients. Chief complaints were recategorized from a multitude of dispatch 'types' into 15 expert consensusdefined categories. Anything not classifiable into these categorized was classified as "other." We report descriptive statistics for key variables. We compare categorical variables using Chi-squared tests.
Results: There were 1,327,831 records from 2013-2015. We excluded 96,097 pregnancy-related calls, 105,186 calls where there was no EMT contact, and 24,578 replicated case IDs, resulting in a final sample of 1,101,9870 records. Overall, 38.3% of calls were for girls (N ¼ 422,370) , much below the most recent census demographics (48.5%, p < 0.001). Most calls were for adolescents (45.8%; N ¼ 445,756); 23.9% were for children < 1 year (N ¼ 222,644), with some states seeing predominately neonates (Tamil Nadu ¼ 71.1%). Primarily, patients were from rural areas (75%; N ¼ 707,210), owned a ration card (84.3%; N ¼ 840,919), and were from socially disadvantaged castes (82.6%, N ¼ 712,163). The most common chief complaints were fever (N ¼ 240,625; 23%), trauma (N ¼ 212,262; 20.3%), and respiratory difficulty (N ¼ 161,122; 14.6%), although this varied by state, age group, and year. Most patients were transported to a government hospital (N ¼ 838,910; 76.1%), with transport patterns varying significantly by age (p for trend < 0.01). There were significant sex-specific differences in chief complaints but not in the type of hospitals to which they were transported. Boys represented 70% of 'trauma' calls whereas girls were overrepresented in 'mental health' calls (63.2%).
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